Lisa Lynn Bendy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa Lynn Bendy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Gaston
Riley Hospital for Children at Indiana University Health
1 shared publication - Don B. Sanders
Department of Pediatrics Indiana University School of Medicine Indianapolis Indiana USA
1 shared publication - James Francis Chmiel
Indiana University School of Medicine and Riley Hospital for Children, Indianapolis, IN, USA
1 shared publication - Jorge Moises Gonzales Cordova
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication - Michael Denning Davis
Dr. Davis is affiliated with Wells Center for Pediatric Research/Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children at Indiana University School of Medicine, Indianapolis, Indiana, USA
1 shared publication - Pi Chun Cheng
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine Riley Hospital for Children Indianapolis Indiana USA
1 shared publication
Latest Publications
- Open Access
- 31 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11)
Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR
Cystic Fibrosis (CF) is a common genetic disease in the United States, resulting from mutations in the Cystic Fibrosis transmembrane conductance regulator (cftr) gene. CFTR modulators, particularly Elexacaftor/Tezacaftor/Ivacaftor (ETI), have significantly improved clinical outcomes for patients with CF. However, many CFTR mutations are not eligible for CFTR modulator therapy due to their rarity. In this study, we report that a patient carrying rare complex CFTR mutations, c.1680-877G>T and c.3067_3072delATAGTG, showed positive clinical outcomes after ETI treatment. We demonstrate that ETI was able to increase the expression of CFTR harboring c.3067_3072delATAGTG in a heterologous system. Importantly, patient-derived nasal epithelial cells in an air–liquid interface (ALI) culture showed improved CFTR function following ETI treatment. These findings supported the initiation of ETI with the patient. Retrospective studies have suggested that the patient has shown small but steady improvement over the past two years in several clinical metrics, including lung function, body mass index (BMI), and sweat chloride levels. Our studies suggest that ETI could be beneficial for patients carrying c.3067_3072delATAGTG.
- 31 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11)
Open AccessElexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR
Cystic Fibrosis (CF) is a common genetic disease in the United States, resulting from mutations in the Cystic Fibrosis transmembrane conductance regulator (cftr) gene. CFTR modulators, particularly Elexacaftor/Tezacaftor/Ivacaftor (ETI), have significantly improved clinical outcomes for patients with CF. However, many CFTR mutations are not eligible for CFTR modulator therapy due to their rarity. In this study, we report that a patient carrying rare complex CFTR mutations, c.1680-877G>T and c.3067_3072delATAGTG, showed positive clinical outcomes after ETI treatment. We demonstrate that ETI was able to increase the expression of CFTR harboring c.3067_3072delATAGTG in a heterologous system. Importantly, patient-derived nasal epithelial cells in an air–liquid interface (ALI) culture showed improved CFTR function following ETI treatment. These findings supported the initiation of ETI with the patient. Retrospective studies have suggested that the patient has shown small but steady improvement over the past two years in several clinical metrics, including lung function, body mass index (BMI), and sweat chloride levels. Our studies suggest that ETI could be beneficial for patients carrying c.3067_3072delATAGTG.